Avista Capital Partners is a venture capital fund based in New York, investing in biotech and pharmaceutical companies at the series C stage. Writing checks from $500,000 to $10 million, Avista targets firms with strong management, steady cash flows, and growth potential. Their portfolio includes companies like OptiNose. Avista leverages seasoned professionals to provide strategic insights and operational guidance.